Quarterly report (Form 10-Q)
Bristol Myers Squibb 10-Q for Quarter ended Sep 30, 2026
Filing excerpt
International revenues were relatively flat during the third quarter of 2026 and increased 5% year-to-date, primarily due to higher demand across the Growth Portfolio, offset by generic erosion within the Legacy Portfolio.